In a report released today, Phil Nadeau from Cowen & Co. maintained a Buy rating on Frequency Therapeutics (FREQ). The company’s shares closed last Monday at $15.93.
According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.3% and a 46.6% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Frequency Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $27.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $17.17 and a one-year low of $11.17. Currently, Frequency Therapeutics has an average volume of 174.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Frequency Therapeutics, Inc. is a clinical-stage biotechnology company. It engages in the development of small molecule drugs that activate progenitor cells within the body to restore healthy tissue.
Read More on FREQ:
